In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.

Published Date: 03 Jun 2024

surprisingly provides a potential boost to overall survival, according to researchers.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Cancer Warnings on Alcohol? Surge in GI Illnesses; Swab Detects Kids' Asthma Type

2.

EMA OKs Two Treatments for Small Cell Lung Cancer

3.

Tafasitamab-Based Combination Boosts PFS in Relapsed/Refractory Follicular Lymphoma

4.

Personalized Breast Cancer Treatment; Insights Into HPV in Men; Exercise and Cancer

5.

Prostate cancer, rectal exams, Casgevy approved for thalassemia, and two million cancer cases.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot